FDA Fast-Track designation

Fort Worth’s AyuVis Gets FDA Fast‑Track Designation for Its Drug for Babies with a Chronic Lung Disease

by | Aug 23, 2024
Premature babies diagnosed with bronchopulmonary dysplasia (BPD) face the risk of rehospitalization, delayed brain development, and respiratory problems throughout childhood. No FDA-approved therapies are available for BPD—which is why the new FDA designation for AyuVis's drug candidate, AVR-48, could lead to game-changing impact.
MORE